| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
Of 190 patients with acute myeloid leukemia (AML), mutations in the FLT3-ITD, NPM1, and CEBPA genes were detected in 18%, 23% and 12%, respectively. AML patients with FLT3-ITD or without any mutation had a poor clinical outcome. In addition, 8% and 10% showed IDH1 and IDH2 mutations. IDH2 mutation was associated with a poor overall survival. Of patients lacking these mutations, we identified deletion mutations in the RNA binding protein TIS11D. Wild-type TIS11D induced growth inhibition and an S phase checkpoint response, while the deletion mutant showed a diminished effect. We establish the prognostic factors in AML according to these results.
|
